

Cover Story
By Matthew Bin Han Ong
NCI is using a hub-and-spoke structure to engineer an ambitious data federation for pediatric cancers—which, if done right, is anticipated to become the gold standard for a new generation of comprehensive cancer databases.
In Brief


Funding Opportunities
Clinical Roundup
Drugs & Targets


NCI Trials


NCI Trials for December 2020
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Vinay Prasad to CBER employees: “It is not wise for FDA to further pollute the scientific literature with papers we cannot defend”















